Bioventus Stock Analysis

BVS Stock  USD 7.07  0.09  1.26%   
Bioventus is overvalued with Real Value of 5.4 and Target Price of 4.5. The main objective of Bioventus stock analysis is to determine its intrinsic value, which is an estimate of what Bioventus is worth, separate from its market price. There are two main types of Bioventus' stock analysis: fundamental analysis and technical analysis.
The Bioventus stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Bioventus is usually not traded on Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Bioventus Stock trading window is adjusted to America/New York timezone.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioventus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.

Bioventus Stock Analysis Notes

About 60.0% of the company shares are held by institutions such as insurance companies. The book value of Bioventus was currently reported as 2.69. The company has Price/Earnings To Growth (PEG) ratio of 2.14. Bioventus recorded a loss per share of 0.33. The entity had not issued any dividends in recent years. Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the bodys natural healing process in the United States and internationally. The company was founded in 2011 and is headquartered in Durham, North Carolina. Bioventus Inc operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1160 people. For more info on Bioventus please contact Kenneth Reali at 919 474 6700 or go to https://www.bioventus.com.

Bioventus Quarterly Total Revenue

129.46 Million

Bioventus Investment Alerts

Bioventus is way too risky over 90 days horizon
Bioventus appears to be risky and price may revert if volatility continues
Bioventus has 409.48 M in debt with debt to equity (D/E) ratio of 1.17, which is OK given its current industry classification. Bioventus has a current ratio of 0.92, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Bioventus to invest in growth at high rates of return.
The entity reported the last year's revenue of 512.35 M. Reported Net Loss for the year was (96.74 M) with profit before taxes, overhead, and interest of 302.71 M.
About 60.0% of Bioventus shares are held by institutions such as insurance companies
Latest headline from bizjournals.com: Durham company agrees to 15 million settlement in shareholder lawsuit

Bioventus Upcoming and Recent Events

29th of March 2024
Upcoming Quarterly Report
View
21st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Bioventus Largest EPS Surprises

Earnings surprises can significantly impact Bioventus' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-10
2022-03-310.050.04-0.0120 
2021-08-10
2021-06-300.140.160.0214 
2022-11-08
2022-09-300.120.08-0.0433 
View All Earnings Estimates

Bioventus Environmental, Social, and Governance (ESG) Scores

Bioventus' ESG score is a quantitative measure that evaluates Bioventus' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Bioventus' operations that may have significant financial implications and affect Bioventus' stock price as well as guide investors towards more socially responsible investments.

Bioventus Thematic Classifications

In addition to having Bioventus stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Medical Equipment Idea
Medical Equipment
USA Equities from Medical Equipment industry as classified by Fama & French

Bioventus Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Susquehanna International Group, Llp2024-03-31
289.6 K
Marshall Wace Asset Management Ltd2024-03-31
240.4 K
Lsv Asset Management2024-03-31
225 K
Goldman Sachs Group Inc2024-03-31
214.3 K
Charles Schwab Investment Management Inc2024-03-31
185.7 K
Jane Street Group, Llc2023-12-31
155.7 K
Alberta Investment Management Corp2024-03-31
152.2 K
Two Sigma Advisers, Llc2024-03-31
141.2 K
Mariner Wealth Advisors, Llc2024-03-31
136.1 K
Essex Woodlands Health Ventures2024-03-31
13 M
Juniper Investment Co, Llc2024-03-31
6.8 M
Note, although Bioventus' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bioventus Market Capitalization

The company currently falls under 'Small-Cap' category with a total capitalization of 457.01 M.

Bioventus Profitablity

The company has Net Profit Margin of (0.04) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of 0.04 %, which entails that for every 100 dollars of revenue, it generated $0.04 of operating income.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.49)(0.46)
Return On Capital Employed 0.03  0.02 
Return On Assets(0.19)(0.18)
Return On Equity(0.90)(0.85)

Management Efficiency

Bioventus has Return on Asset of 0.0152 % which means that on every $100 spent on assets, it made $0.0152 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1187) %, meaning that it generated no profit with money invested by stockholders. Bioventus' management efficiency ratios could be used to measure how well Bioventus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.46 in 2024. Return On Capital Employed is likely to drop to 0.02 in 2024. At this time, Bioventus' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 3.3 M in 2024, whereas Other Current Assets are likely to drop slightly above 12.7 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 2.77  2.99 
Tangible Book Value Per Share(4.29)(4.50)
Enterprise Value Over EBITDA 9.58  9.10 
Price Book Value Ratio 1.90  1.81 
Enterprise Value Multiple 9.58  9.10 
Price Fair Value 1.90  1.81 
Enterprise Value702.7 M1.2 B
The analysis of Bioventus' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Bioventus' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Bioventus Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Operating Margin
0.0434
Profit Margin
(0.04)
Beta
0.837
Return On Assets
0.0152
Return On Equity
(0.12)

Technical Drivers

As of the 18th of July 2024, Bioventus shows the Risk Adjusted Performance of 0.1076, downside deviation of 3.07, and Mean Deviation of 3.05. Bioventus technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Bioventus coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Bioventus is priced correctly, providing market reflects its regular price of 7.07 per share. Given that Bioventus has jensen alpha of 0.7699, we suggest you to validate Bioventus's prevailing market performance to make sure the company can sustain itself at a future point.

Bioventus Price Movement Analysis

Execute Study
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Bioventus middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Bioventus. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Bioventus Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bioventus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bioventus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bioventus insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Bioventus Outstanding Bonds

Bioventus issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bioventus uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bioventus bonds can be classified according to their maturity, which is the date when Bioventus has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Bioventus Predictive Daily Indicators

Bioventus intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bioventus stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Bioventus Corporate Filings

13A
15th of July 2024
An amended filing to the original Schedule 13G
ViewVerify
F4
25th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
24th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
21st of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
18th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
17th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
13th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
11th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify

Bioventus Forecast Models

Bioventus' time-series forecasting models are one of many Bioventus' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bioventus' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Bioventus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bioventus prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bioventus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bioventus. By using and applying Bioventus Stock analysis, traders can create a robust methodology for identifying Bioventus entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.24)(0.25)
Operating Profit Margin 0.03  0.03 
Net Loss(0.30)(0.29)
Gross Profit Margin 0.62  0.77 

Current Bioventus Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bioventus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bioventus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
4.5Buy3Odds
Bioventus current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Bioventus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bioventus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bioventus, talking to its executives and customers, or listening to Bioventus conference calls.
Bioventus Analyst Advice Details

Bioventus Stock Analysis Indicators

Bioventus stock analysis indicators help investors evaluate how Bioventus stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bioventus shares will generate the highest return on investment. By understating and applying Bioventus stock analysis, traders can identify Bioventus position entry and exit signals to maximize returns.
Begin Period Cash Flow30.2 M
Long Term Debt367 M
Common Stock Shares Outstanding62.6 M
Total Stockholder Equity173.6 M
Tax Provision-16.3 M
Property Plant And Equipment Net50 M
Cash And Short Term Investments37 M
Cash37 M
Accounts Payable23 M
Net Debt372.5 M
50 Day M A6.2352
Total Current Liabilities175.5 M
Other Operating Expenses496.3 M
Non Current Assets Total542.9 M
Forward Price Earnings25.7069
Non Currrent Assets Other3.1 M
Stock Based Compensation2.7 M

Additional Tools for Bioventus Stock Analysis

When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.